Glaukos (GKOS) vs Haemonetics (HAE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haemonetics (HAE) has outperformed Glaukos (GKOS) over the past year, gaining 134.3% versus a gain of 84.1%. Over five years, GKOS leads with a +259.9% price change compared with +70.9% for HAE. Glaukos is the larger company by market cap ($9.51 billion vs $5.44 billion), about 1.8 times the size.
On valuation, Haemonetics trades at a lower forward P/E (20.5x vs 308.1x for Glaukos). Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | HAE |
|---|---|---|
| Share price | $161.29 | $119.47 |
| Market cap | $9.51B | $5.44B |
| 1-day change | -6.32% | +17.46% |
| YTD return | +42.85% | +49.06% |
| 1-year return | +84.14% | +134.35% |
| 5-year return | +259.86% | +70.89% |
| P/E ratio (TTM) | — | 57.71 |
| Forward P/E | 308.06 | 20.53 |
| EPS (TTM) | $-3.26 | $2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $1.33B |
| Revenue growth (YoY) | +32.33% | -1.97% |
| Net income (latest FY) | $-187.69M | $97.31M |
| Gross margin | 55.72% | 59.04% |
| Operating margin | -39.33% | 11.75% |
| Net margin | -36.99% | 7.29% |
| 52-week high | $191.62 | $121.00 |
| 52-week low | $73.16 | $48.17 |
| Distance from 52-week high | -15.83% | -1.26% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.19% | -6.67% |
| Average volume | 831.71K | 715.68K |
| Shares outstanding | 58.98M | 45.50M |
| Employees | 1,094 | 3,009 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed GKOS by 50.2 percentage points over the past year.
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs -1.97%).
- The two companies sit in different sectors: Glaukos in Healthcare and Haemonetics in Health Care.
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Healthcare · Medical Devices · 1,094 employees
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
GKOS vs HAE FAQ
Which is bigger, Glaukos or Haemonetics?
Glaukos (GKOS) is larger, with a market capitalization of $9.51B compared with $5.44B for Haemonetics (HAE).
Which stock has performed better over the past year, GKOS or HAE?
HAE returned +134.35% over the past 12 months, compared with +84.14% for GKOS (price return, excluding dividends). Past performance does not predict future results.
Are Glaukos and Haemonetics in the same industry?
No. Glaukos is in the Healthcare sector, while Haemonetics is in Health Care.